Cofoe Medical Technology Co., Ltd. (1187.HK / 301087.SZ)

Deep-Dive Research Report — July 2026

Section 1: What the Company Does

Cofoe Medical makes the medical devices that people use at home rather than in a hospital. Think of the drawer or cupboard in an ageing parent's house that holds a blood-pressure cuff, a blood-glucose meter, a thermometer, a pulse oximeter; the wheelchair or walker in the hallway; the hearing aid on the nightstand; the CPAP machine by the bed; the adult diapers and the box of plasters. Cofoe designs, manufactures, brands and sells that entire cupboard. It carries more than 200 product categories and over 10,000 SKUs under a single master brand, "Cofoe" (可孚), and sells them through e-commerce (Tmall, JD.com), chain pharmacies, its own retail stores, and, increasingly, exports to more than 60 countries.

The company was built by one person working backwards from distribution. Founder and chairman Zhang Min (张敏, born November 1979, EMBA from Central South University) started in 2000 as an agent reselling other manufacturers' home medical devices - blood-pressure monitors, wheelchairs, sanitary supplies, cupping sets. In November 2007 he founded "Good Nurse" (好护士), a chain of medical-device specialty stores and warehouse mega-stores across Hunan, Zhejiang, Hubei and Guangxi. Cofoe Medical Technology itself was incorporated in 2009 in Changsha, Hunan. The pivotal decision came when Zhang stopped being a middleman and moved upstream into R&D and manufacturing, converting a retail and distribution business that already understood the Chinese home-care customer into a vertically integrated own-brand manufacturer. That sequence - channel first, brand second, factory third - is unusual and explains a lot about the company today: Cofoe knows how to sell to Chinese households at scale, and it back-filled the ability to make the products it was already good at selling.

The core value proposition is breadth plus affordability under one trusted consumer brand. A Chinese family managing a chronic condition or caring for an elderly relative does not want to source a thermometer from one vendor, a wheelchair from another and a nebuliser from a third. Cofoe offers the whole basket at accessible price points, backed by a recognisable brand and a physical service footprint (its stores double as hearing-aid fitting and after-sales centres). The technical difficulty is not any single device - most individual products are not frontier technology - it is doing all of them at once: running R&D, regulatory registration, manufacturing, quality control, omni-channel retail and after-sales across 200+ categories simultaneously, at a cost structure that survives Chinese e-commerce price competition.

By its own account and third-party industry data cited at IPO, Cofoe ranks second among home-care medical-device companies in China and first in rehabilitation assistive products. On May 6, 2026 it became the first Chinese home-medical-device maker to achieve an "A+H" dual listing, raising about HK$1.06 billion (roughly US$136 million).

Section 2: Business Segments

Cofoe reports five product lines. The following mix is from the FY2025 annual report (revenue RMB 3.387 billion, +13.56% year on year; net profit attributable to shareholders RMB 372 million, +19.20%).

Rehabilitation Aids (康复辅具) - RMB 1.244bn, ~36.7% of revenue, +12.68%

The largest segment and the one where Cofoe claims the number-one position in China. It spans wheelchairs, commode chairs, canes, rollators/walkers, nursing beds, air mattresses, posture-correction braces (矫姿带), and hearing aids. Two things make this segment strategically central. First, it includes hearing aids, which management treats as the next big growth engine - a category with a large, under-penetrated ageing population in China and a value-for-money gap between cheap unbranded amplifiers and expensive Western premium brands, into which Cofoe positions itself with fitting services in its own stores. Second, it houses the well-known consumer posture-corrector brand Beibeijia (背背佳), an acquired mass-market brand that is a meaningful revenue contributor and gives Cofoe consumer-marketing reach beyond the clinical channel. The core capability here is the marriage of a physical retail/service network with device manufacturing - hearing aids in particular require in-person fitting, which favours a player with stores. This is both the cash base and, via hearing, the growth bet.

Medical Care / Nursing (医疗护理) - RMB 0.912bn, ~26.9% of revenue, +13.76%

Consumables and nursing supplies: adult diapers, ostomy bags, wound care and plasters (band-aids), protective and hygiene supplies. This is the razor-blade of the portfolio - lower unit price, repeat purchase, high volume, driven by demographics (incontinence and post-surgical care in an ageing population). It is the steadiest, most consumable-like revenue stream and underpins customer repeat rates on e-commerce. Competitive intensity is high because barriers per product are low, so this segment competes on brand trust, distribution and cost.

Health Monitoring (健康监测) - RMB 0.587bn, ~17.3% of revenue, +20.08%

The classic home-diagnostics basket: blood-pressure monitors, blood-glucose meters and test strips (including a combined glucose-and-uric-acid strip), thermometers (including a pre-warming design), fingertip pulse oximeters, fetal dopplers, and in-vitro diagnostic kits (HCG, H. pylori, respiratory-infection tests). This was the fastest-growing of the large segments in FY2025 (+20%). It is the most technology- and registration-intensive of the everyday categories and the one where global peers (Omron in BP, Sinocare in glucose) are strongest, so it is a genuine competitive battleground rather than a stronghold.

Respiratory Support (呼吸支持) - RMB 0.265bn, ~7.8% of revenue, -0.67% full year

CPAP/BPAP sleep-apnea machines, non-invasive ventilators, oxygen concentrators and nebulisers. This segment was roughly flat for the full year but that headline hides an inflection: management reported respiratory revenue up 80.18% in the second half of 2025, driven by a self-developed "smart connected" (智能网联) ventilator ramping quickly. The full-year flatness reflects a tough comparison base from the post-COVID respiratory-demand normalisation. Strategically this is the highest-technology segment and the one where a successful in-house ventilator would most improve both mix and margin - it is the option-value line.

TCM Physiotherapy and Other (中医理疗及其他) - RMB 0.244bn, ~7.2% of revenue, +35.14%

Traditional-Chinese-medicine home therapy devices: moxibustion products, massage, cupping, traction. Smallest segment but fastest-growing (+35%). It is culturally specific to China, hard for Western competitors to serve, and rides a domestic wellness/self-care consumer trend. A small but high-growth strategic option with a defensible local flavour.

Section 3: Products and Business Detail

Catalogue. Cofoe's public catalogue reads like a home-health department store: blood-pressure monitors, blood-glucose meters and strips (including a glucose/uric-acid dual strip), infrared and pre-warming thermometers, fingertip pulse oximeters, fetal dopplers; nebulisers, oxygen concentrators, CPAP/BPAP and non-invasive ventilators; wheelchairs, commode chairs, nursing beds, air mattresses, canes, rollators, posture braces, hearing aids; adult diapers, ostomy bags, wound care and plasters; moxibustion, massage, cupping and traction devices; and a family of in-vitro diagnostic reagents and test kits (HCG, H. pylori, DNA/RNA extraction, respiratory-tract infection panels). Over 200 categories and 10,000+ SKUs sit under the single "Cofoe" master brand, supplemented by the acquired Beibeijia posture-corrector brand.

What makes it hard. No single product is exotic, but each class of device carries its own Chinese NMPA medical-device registration and quality-system burden, and the diagnostics and respiratory lines require the most process knowledge (reagent chemistry, ventilator control electronics and software, and the "smart connected" networking layer Cofoe added to its ventilator). The genuinely hard thing is running R&D, registration, manufacturing and quality across all of these simultaneously while holding a cost structure that survives Tmall/JD price wars. Cofoe operates three R&D centres and five production bases, with manufacturing sites in Changsha, Xiangyin, Nantong and Qidong. Vertical integration into own-manufacture (rather than pure OEM sourcing) is what lets it protect margin as volumes scale and is the payoff from Zhang Min's decision to move upstream.

Channels. Distribution is genuinely omni-channel and is the company's deepest moat. Online, the Cofoe brand leads multiple medical-device categories on Tmall and JD.com. Offline, it runs a self-operated store network (reported in the 430-600 range across sources) that serves double duty as hearing-aid fitting and after-sales service centres, and it supplies dozens of chain-pharmacy groups. The company says it reaches 50 million households.

Geographies and exports. Cofoe exports to more than 60 countries, with named markets including the United States, Mexico, Chile, Germany, Spain, Italy, Turkey and the Middle East. International is small today but is the explicit use-of-proceeds priority from the H-share IPO: management named the UK, Italy, the US, Mexico, India, Thailand and the Philippines as expansion targets. The May 2026 A+H listing is itself the milestone that funds this - the first dual listing by a Chinese home-medical-device maker.

Section 4: Customers

The end customer is the Chinese household - specifically the middle-aged adult buying for an ageing parent or managing their own chronic condition (hypertension, diabetes, sleep apnea, incontinence, hearing loss). This is a consumer-health buyer, not a hospital procurement officer, and that shapes everything: the decision is made by an individual or family, the price sensitivity is high, brand trust and reviews matter enormously, and the sales cycle is effectively instant (an e-commerce add-to-cart) rather than a months-long tender.

Three buying contexts matter. Online consumers on Tmall and JD choose on brand recognition, price, ratings and breadth (the convenience of one trusted brand for the whole basket). Pharmacy walk-ins rely on the pharmacist's recommendation and shelf presence, so Cofoe's chain-pharmacy relationships and brand pull are the decisive factors. Store customers, especially for hearing aids and complex rehabilitation equipment, need in-person fitting, demonstration and after-sales service, which is exactly what the self-operated store network provides and what pure e-commerce competitors cannot replicate.

Switching costs at the individual-product level are low - a consumer can buy a rival thermometer next time - but they are meaningfully higher for the categories that involve fitting, service or a subscription of consumables. A hearing-aid customer fitted at a Cofoe store, or a CPAP user tied to Cofoe's masks and consumables, or a household in a repeat-purchase relationship for glucose strips and diapers, is stickier than the device price alone suggests. Concentration risk is low: revenue is spread across millions of households and many channel partners rather than a handful of large accounts, which makes revenue diversified but also means no single contract underwrites it - demand must be re-won every purchase cycle. Contract structure is overwhelmingly transactional/spot (consumer sales) with recurring dynamics coming from consumables reorders rather than long-term supply agreements. This is closer to a branded consumer-goods revenue model than a capital-equipment one, with the predictability that comes from repeat consumable purchases and the fragility that comes from having no contracted backlog.

One data-quality flag from the most recent filing: in Q1 2026 accounts receivable rose to about 115% of the latest annual net profit, and selling/admin/finance expenses reached ~39% of revenue. That points to growing reliance on channel/distributor credit terms as the company pushes volume and international expansion - a customer-quality dynamic worth watching (see Section 8).

Section 5: Competitive Landscape

China's home-medical-device market is fragmented at the product level but consolidating at the brand level, and Cofoe competes in a different way in each segment. Its structural advantage is breadth and channel - very few rivals span all five segments with one consumer brand and a physical service network. Its structural exposure is that in each individual category it faces a specialist that is often larger and more focused.

The most important rival is Yuwell (鱼跃医疗, 002223.SZ), the clear domestic leader and the company most directly comparable to Cofoe across respiratory, monitoring and rehabilitation. Yuwell is bigger and stronger in respiratory (oxygen concentrators, ventilators) and hospital-adjacent equipment; Cofoe generally competes below it on price and leads it in rehabilitation assistive products and in consumer-brand marketing reach. In glucose monitoring Cofoe faces Sinocare (三诺生物, 300298.SZ), a glucose/CGM specialist. In blood-pressure and home monitoring the benchmark is Japan's Omron (Omron Healthcare), the global category standard on quality and accuracy - Cofoe competes on price and local distribution rather than technology leadership. Andon Health (九安医疗, 002432.SZ) overlaps in home BP monitoring and connected health. In hearing aids, the premium tier is held by Western players (Sonova, Demant, WS Audiology, GN) while Cofoe attacks the value segment with in-store fitting - a positioning gap rather than a head-to-head fight.

Barriers to entry are real but not absolute. They are: the NMPA registration burden across 200+ categories, a manufacturing and quality base built over 15+ years, and - most durably - the omni-channel distribution and brand trust that would take a new entrant years and heavy marketing spend to replicate. What the barriers do not provide is pricing power on any single commodity device; e-commerce keeps margins competitive, which is why Cofoe's ~54% gross margin (Q3 2025) coexists with a high and rising selling-expense ratio. The honest read: Cofoe's moat is the portfolio-plus-channel system, not any one product; where it is exposed is head-to-head against a better-resourced specialist in a single high-tech category.

Market-cap figures move; treat them as peer-size reference only, as of the dates shown.

Section 6: Industry

Demand for home medical devices in China is driven by a small number of powerful structural forces. The dominant one is demographics: China is ageing rapidly, and an older population needs chronic-disease monitoring (hypertension, diabetes), mobility and rehabilitation aids, incontinence and nursing consumables, hearing aids, and respiratory support. Layered on top is rising chronic-disease prevalence, a policy push toward home-based and community care to relieve hospital load, growing health awareness and disposable income, and the e-commerce infrastructure that made it trivial for a household to buy medical devices online. These are secular tailwinds rather than cyclical ones, which is the industry's most attractive feature - unit demand for a glucose strip or an adult diaper does not fall much in a recession.

The market is large and growing at a healthy clip. Independent industry commentary on China's home-medical-device market points to a multi-hundred-billion-RMB category growing at a double-digit CAGR, with home care specifically identified as one of the faster-growing slices of Chinese medtech. Cofoe cites third-party rankings placing it second in home-care devices and first in rehabilitation assistive products.

On the supply chain, China is both the world's factory for many of these commodity devices and an increasingly self-sufficient consumer market. Import substitution runs in Cofoe's favour in the mass/value tiers - domestic brands have displaced imports in BP monitors, thermometers, wheelchairs and consumables - while imports still hold the premium and highest-accuracy tiers (Omron in monitoring, Western brands in premium hearing aids and high-end ventilators). Cofoe's opportunity is to keep climbing from value toward mid-tier as its R&D matures (the in-house "smart connected" ventilator is the clearest example), and, in reverse, to export Chinese-made value devices to price-sensitive markets abroad.

Regulation is a barrier and a moat: every device class requires NMPA registration and quality-system compliance, and export markets add their own (FDA, CE). This slows new entrants and rewards incumbents with broad registered portfolios. Cyclicality is low at the demand level but the industry did experience a genuine cycle around COVID - a 2020-2022 surge in thermometers, oximeters, oxygen concentrators and IVD, followed by a normalisation that shows up as tough comparison bases (visible in Cofoe's flat full-year respiratory line). The industry-level headwinds are e-commerce price competition compressing device margins and the marketing-spend intensity required to win the consumer; the tailwinds are demographics, policy and import substitution.

Section 7: Growth Triggers

Sourced from Cofoe's statutory reporting periods and results-briefing / IPO commentary (Chinese A-share issuers do not publish English earnings-call transcripts; the "reporting periods" used are FY2024, Q1 2025, H1 2025, Q3 2025, FY2025 and Q1 2026, plus the May 2026 H-share IPO disclosures).

• In-house "smart connected" ventilator ramp in respiratory (FY2025 annual report / results briefing, ~Mar 2026). Management reported respiratory revenue up 80.18% in H2 2025 driven by the self-developed intelligent networked ventilator "achieving rapid volume." This is the clearest near-term mix and margin lever.

• Hearing-aid expansion as the "next Cofoe" (repeated theme, FY2024 through FY2025 reporting). Management frames hearing health as a large under-penetrated category and is building fitting and service capacity in its store network. Repeated across multiple periods.

• International expansion funded by the H-share IPO (H-share prospectus / listing, May 6, 2026). Proceeds earmarked for global expansion into the UK, Italy, the US, Mexico, India, Thailand and the Philippines, on top of the existing 60+ export markets.

• Health-monitoring product refresh driving the fastest large-segment growth (FY2025 annual report). The glucose-and-uric-acid dual test strip and a pre-warming thermometer were cited as reasons the monitoring segment grew ~20%.

• TCM physiotherapy scaling from a small base (FY2025 annual report). +35% growth in TCM and other, a locally defensible category with room to run.

• Domestic channel and brand-marketing build-out (H-share prospectus, May 2026). Proceeds allocated to expanding domestic sales channels (self-operated stores and pharmacy partnerships) and brand promotion, including the Beibeijia consumer brand.

• Continued top-line acceleration into 2026 (Q1 2026 report, ~Apr 30, 2026). Q1 2026 revenue grew 37.22% year on year to RMB 1.012 billion, a sharp acceleration versus the ~13.6% FY2025 rate - though profit grew slower (see Walk the Talk and Risks).

Section 8: Key Risks

Margin compression from rising selling expense and slowing profit conversion. This is the most concrete, present-tense risk. In Q1 2026 revenue grew 37% but net profit grew only 17%, net margin fell to ~10.6% (down ~14.5% year on year), and the three expense lines (selling, admin, finance) reached ~39% of revenue. The mechanism: winning the Chinese home-health consumer and expanding abroad both cost heavy marketing and channel spend, and if revenue is being bought with margin, the quality of the growth degrades. High probability, moderate-to-serious drag - it is already happening.

Accounts-receivable build. Q1 2026 receivables reached ~115% of the latest full-year net profit. As Cofoe pushes volume through distributors and new export markets, it is extending more credit; if collection slows or channel partners weaken, this converts into impairments and cash-flow strain. Moderate probability, moderate impact, and directly visible in filings.

Single-product moat weakness / commoditisation. Cofoe's strength is the system, not any one device. In each high-tech category it faces a larger specialist (Yuwell in respiratory, Sinocare in glucose, Omron in BP, Western brands in premium hearing). E-commerce keeps device prices under permanent pressure. If Cofoe cannot keep climbing the technology ladder (the ventilator being the test case), it stays stuck in low-margin value tiers. High probability, structural.

Post-COVID normalisation and comparison bases. The full-year flat respiratory line shows how the 2020-2022 demand surge still distorts comparisons. Categories that boomed during COVID (IVD, oximeters, thermometers) can disappoint against inflated bases. Moderate probability, segment-specific.

Execution and capital-allocation risk on overseas expansion. The seven named new markets each carry their own regulatory (FDA/CE), distribution and brand-building costs. International is small today; if the IPO proceeds are spent building presence that does not scale, it is a multi-year drag on returns. Moderate probability, moderate impact, deferred.

Founder concentration and governance. Zhang Min controls the company and, per the HKEX disclosure below, holds a large concentrated stake. Founder-led focus is a strength, but key-person dependence and concentrated control are governance risks for minority H-share holders, who sit behind an A-share-dominated capital structure.

Brand/quality event. With 200+ device categories reaching 50 million households, a single quality or safety failure in a monitoring or respiratory product could damage the master-brand trust that is the whole moat. Low probability, high impact.

Section 9: Walk the Talk

The six reporting periods used, oldest to newest: FY2024 annual (released ~Apr 29, 2025), Q1 2025 (~Apr 30, 2025), H1 2025 interim (Aug 26, 2025), Q3 2025 (~Oct 2025), FY2025 annual (~Mar/Apr 2026), and Q1 2026 (~Apr 30, 2026). The most recent, Q1 2026, is within ~90 days of today. Note again that these are statutory filings and Chinese-language results briefings, not English earnings calls; management "guidance" in this system is qualitative and lighter than a US-style outlook, so the credibility read is built from delivered results and repeated strategic commitments rather than precise numerical guides.

Across FY2024 into FY2025, management consistently framed three priorities: revive respiratory with an in-house intelligent ventilator, build hearing aids into a second growth pillar, and pursue an A+H listing to fund internationalisation. On the first, they delivered visibly - the FY2025 report showed respiratory swinging from a flat full year to +80% in H2 on the self-developed ventilator, which is a specific, checkable claim that matches the strategic promise. On the third, they delivered unambiguously: the A+H listing that had been discussed since the 2025 HKEX application (submitted August 2025) closed on May 6, 2026, exactly as planned, making Cofoe the first home-medical-device A+H issuer. That is a promise kept on schedule.

The tension in the record is between top-line ambition and profit discipline. FY2025 was clean: revenue +13.6% and profit +19.2%, i.e. profit growing faster than revenue - the mark of a company converting scale into earnings. Q1 2026 inverted that: revenue accelerated hard to +37% but profit grew only +17% and margins fell. Management can point to genuine investment (overseas build-out, channel expansion, the ventilator ramp) as the reason, and that is a coherent story. But it means the most recent data point shows management buying growth with margin, which is exactly the risk investors should hold them to over the next few reporting periods. The receivables build in the same quarter reinforces that the growth is being pushed through channels aggressively.

There is also a smaller consistency signal worth crediting: dividends. Management raised the payout each year (FY2024 RMB 1.00/share; FY2025 RMB 1.20/share final plus a RMB 0.60 interim) and ran a share buyback, which is behaviourally consistent with a management team that says it is shareholder-focused. That is a promise-adjacent action that was actually taken.

The plain assessment: this is a management team that has done the big things it said it would - the ventilator turnaround and the A+H listing are both concrete, dated, delivered promises. The open question is not whether they execute strategically (they do) but whether the current sprint for revenue growth and overseas presence is being funded at an acceptable cost to margins and cash. Credible on strategy; on watch for financial discipline.

Section 10: Shareholder Friendliness Index

Dividends. Cofoe pays and has been raising its dividend. For FY2024 it distributed RMB 10 per 10 shares (RMB 1.00/share). For FY2025 it distributed a final RMB 12 per 10 shares (RMB 1.20/share) plus a RMB 6 per 10 shares (RMB 0.60/share) interim, so the full-year 2025 cash return stepped up year on year (FY2025 final cash dividend ~RMB 246 million on the 205.0 million shares eligible after excluding treasury). The trend is up across the last two annual cycles, which given FY2025 net profit of RMB 372 million implies a moderate, sustainable payout rather than a strained one. (The FY2023 per-share figure was not separately verified in this search; the two most recent years both show growth.)

Buybacks and dilution. Cofoe executed a share buyback and holds 3,878,731 repurchased shares in treasury (excluded from the FY2025 dividend), out of ~208.9 million total shares - roughly 1.9% of capital retired/parked via buyback. The May 2026 H-share IPO issued 27 million new H shares, so on a total-company basis the share count grew from the primary raise (dilution to fund international expansion, not routine option dilution), while the domestic A-share count has been modestly reduced by the buyback. Net: A-share holders have seen a small buyback plus rising dividends; the overall share count rose because of the deliberate, capital-raising H-share issuance. Buyback data window note: the MoatMap database recorded zero HKEX buybacks in the trailing ~90 days (its coverage window; last scrape 2026-07-03, ~49h stale at the time of writing), which is expected given the H-shares are only two months old; the treasury buyback described above is the A-share programme sourced from the FY2025 dividend filing, not the 90-day HKEX window.

Verdict: Returns Capital (moderately). Cofoe pays a rising dividend and runs a buyback; the growing share count reflects a one-off growth-funding IPO rather than shareholder-unfriendly dilution.

Section 11: Insider Activities

Source note: Hong Kong's HKEX Disclosure of Interests portal is gated to automated retrieval, so per the standing convention the MoatMap cross-market disclosure database is the sole source for recent HKEX insider dealing here. The MoatMap feed is flagged stale - last scrape 2026-07-03 23:38 UTC (~49h before this report) - so filings in the last two days may be missing. The H-shares have only traded since May 6, 2026, so the 12-month window is effectively a two-month window.

Recent transactions (last 12 months):

There is a single recorded filing: Zhang Min, the founder and chairman, associated with 8,000,000 shares representing 29.63% of the relevant class, dated 2026-06-16, classified as "Other" - i.e. a Disclosure of Interest / corporate-action disclosure rather than an open-market purchase or sale. Given the H-share tranche is 27 million shares, a 29.63% figure aligns with a disclosure against the H-share class rather than the ~209 million-share total company. Because the type is "Other" and no price or consideration is disclosed, this should not be read as a conviction open-market buy; it is a holding/interest disclosure consistent with the founder's control position becoming reportable under the new HKEX listing.

Buys - signal read: none recorded. No open-market insider purchase appears in the window.

Sells - signal read: none recorded. No open-market insider disposal appears in the window.

Net assessment: With only two months of H-share history and a single non-trade disclosure, there is no open-market insider buy/sell signal to read either way. The one filing confirms concentrated founder ownership (a governance data point, per Section 8) but carries no directional conviction signal. Net read: neutral - insufficient trading history to signal. This is normal for a company that listed on the venue only nine weeks ago; the picture will become meaningful after the first HKEX interim results (H1 2026, due ~August 2026) and any post-lockup activity.

Section 12: Scenarios

Bull case. The in-house intelligent ventilator that drove H2 2025 respiratory up 80% turns out to be the first of several successful moves up the technology ladder, and Cofoe stops being a value-tier assembler and becomes a genuine mid-tier innovator. Hearing aids become the "second Cofoe" management keeps promising: the store network's fitting advantage compounds as China's ageing population drives penetration, and Cofoe owns the affordable, serviced middle of a market the Western premium brands price themselves out of. The H-share proceeds fund a real overseas franchise - the UK, Italy, the US, Mexico, India and Southeast Asia each become durable export channels rather than pilots - so the growth base broadens beyond China just as domestic demographics keep the home market compounding. Margins stabilise once the overseas build-out matures, receivables normalise, and the market re-rates a broad, branded, demographically tailwind-ed home-health platform that has proven it can both grow and pay a rising dividend.

Base case. Cofoe keeps doing what the last two years show it does: growing the top line at a healthy double-digit-plus rate across a balanced five-segment portfolio, with rehabilitation aids and nursing consumables as the ballast, health monitoring and TCM as the faster movers, and respiratory recovering off its low base. The A+H listing delivers incremental international revenue but internationalisation stays a slow burn rather than a step-change. Margins stay under mild pressure from e-commerce competition and marketing intensity - profit grows, but not dramatically faster than revenue, and occasionally slower (as in Q1 2026) when investment spikes. The dividend keeps rising modestly. It remains the clear number-two to Yuwell, defending its number-one spot in rehabilitation aids, executing competently without any single breakout that transforms the economics.

Bear case. The Q1 2026 pattern - revenue up 37%, profit up only 17%, margins down, receivables at 115% of annual profit - is not a one-quarter investment blip but the start of a structural squeeze. Cofoe finds it is buying growth: the only way to keep the top line rising against Yuwell, Sinocare, Omron and a swarm of cheap e-commerce rivals is heavier marketing and more generous channel credit, and both erode returns and cash. The overseas push absorbs IPO proceeds building presence in seven markets that never reach scale, each a small drag. The ventilator ramp proves to be a one-off rather than a repeatable climb up the technology ladder, so the mix stays commoditised. A collection problem in an over-extended distributor channel forces receivable write-downs, and the market concludes it owns a high-growth, low-quality-of-earnings roll-up of commodity home devices rather than a branded platform with pricing power.